EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Ioana Agache; Cezmi A Akdis; Mubeccel Akdis; Knut Brockow; Tomas Chivato; Stefano Del Giacco; Thomas Eiwegger; Kilian Eyerich; Ana Giménez-Arnau; Jan Gutermuth; Emma Guttman-Yassky; Marcus Maurer; Graham Ogg; Peck Y Ong; Liam O'Mahony; Jürgen Schwarze; Amena Warner; Thomas Werfel; Oscar Palomares; Marek Jutel

doi:10.1111/all.15030

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez-Arnau, Jan Gutermuth, Emma Guttman-Yassky, Marcus Maurer, Graham Ogg, Peck Y Ong, Liam O'Mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek Jutel

Division of Paediatrics and Adolescent Medicine (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Journal article

33 Citations (Scopus)

Abstract

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

Original language	English
Pages (from-to)	17-38
Number of pages	22
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	77
Issue number	1
DOIs	https://doi.org/10.1111/all.15030
Publication status	Published - Jan 2022

Keywords

Adolescent
Adult
Anti-Allergic Agents/therapeutic use
Biological Products/therapeutic use
Child
Chronic Disease
Chronic Urticaria
Humans
Omalizumab/therapeutic use
Treatment Outcome
Urticaria/drug therapy

Access to Document

10.1111/all.15030

Cite this

Agache, I., Akdis, C. A., Akdis, M., Brockow, K., Chivato, T., Del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O'Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., & Jutel, M. (2022). EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy: European Journal of Allergy and Clinical Immunology, 77(1), 17-38. https://doi.org/10.1111/all.15030

@article{0aff69bb314b44deb3065d445bc38fae,

title = "EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old",

abstract = "Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.",

keywords = "Adolescent, Adult, Anti-Allergic Agents/therapeutic use, Biological Products/therapeutic use, Child, Chronic Disease, Chronic Urticaria, Humans, Omalizumab/therapeutic use, Treatment Outcome, Urticaria/drug therapy",

author = "Ioana Agache and Akdis, {Cezmi A} and Mubeccel Akdis and Knut Brockow and Tomas Chivato and {Del Giacco}, Stefano and Thomas Eiwegger and Kilian Eyerich and Ana Gim{\'e}nez-Arnau and Jan Gutermuth and Emma Guttman-Yassky and Marcus Maurer and Graham Ogg and Ong, {Peck Y} and Liam O'Mahony and J{\"u}rgen Schwarze and Amena Warner and Thomas Werfel and Oscar Palomares and Marek Jutel",

note = "Publisher Copyright: {\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",

year = "2022",

month = jan,

doi = "10.1111/all.15030",

language = "English",

volume = "77",

pages = "17--38",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

Agache, I, Akdis, CA, Akdis, M, Brockow, K, Chivato, T, Del Giacco, S, Eiwegger, T, Eyerich, K, Giménez-Arnau, A, Gutermuth, J, Guttman-Yassky, E, Maurer, M, Ogg, G, Ong, PY, O'Mahony, L, Schwarze, J, Warner, A, Werfel, T, Palomares, O & Jutel, M 2022, 'EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old', Allergy: European Journal of Allergy and Clinical Immunology, vol. 77, no. 1, pp. 17-38. https://doi.org/10.1111/all.15030

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. / Agache, Ioana; Akdis, Cezmi A; Akdis, Mubeccel et al.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, No. 1, 01.2022, p. 17-38.

Research output: Journal article (peer-reviewed) › Journal article

TY - JOUR

T1 - EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

AU - Agache, Ioana

AU - Akdis, Cezmi A

AU - Akdis, Mubeccel

AU - Brockow, Knut

AU - Chivato, Tomas

AU - Del Giacco, Stefano

AU - Eiwegger, Thomas

AU - Eyerich, Kilian

AU - Giménez-Arnau, Ana

AU - Gutermuth, Jan

AU - Guttman-Yassky, Emma

AU - Maurer, Marcus

AU - Ogg, Graham

AU - Ong, Peck Y

AU - O'Mahony, Liam

AU - Schwarze, Jürgen

AU - Warner, Amena

AU - Werfel, Thomas

AU - Palomares, Oscar

AU - Jutel, Marek

PY - 2022/1

Y1 - 2022/1

N2 - Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

AB - Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

KW - Adolescent

KW - Adult

KW - Anti-Allergic Agents/therapeutic use

KW - Biological Products/therapeutic use

KW - Child

KW - Chronic Disease

KW - Chronic Urticaria

KW - Humans

KW - Omalizumab/therapeutic use

KW - Treatment Outcome

KW - Urticaria/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85112064104&partnerID=8YFLogxK

U2 - 10.1111/all.15030

DO - 10.1111/all.15030

M3 - Journal article

C2 - 34324716

SN - 0105-4538

VL - 77

SP - 17

EP - 38

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 1

ER -

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this